First-Line Osimertinib in Asian Patients with Advanced EGFR-Mutant Lung Cancer

被引：0
|
作者：
Tan, W. [1 ]
Chua, B. [1 ]
Yin, D. [2 ]
Tan, S. H. [3 ]
Tan, D. [1 ]
Ang, M. [1 ]
Kanesvaran, R. [1 ]
Jain, A. [1 ]
Rajasekaran, T. [1 ]
Lai, G. [1 ]
Toh, C. K. [1 ]
Tan, E. [1 ]
Ng, Q. S. [1 ]
Lim, W. [1 ]
机构：
[1] Natl Canc Ctr Singapore, Med Oncol, Singapore, Singapore
[2] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore
[3] Natl Canc Ctr Singapore, Div Clin Trials & Epidemiol Sci, Singapore, Singapore
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
First-line osimertinib; EGFR-mutant; Asian;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P76.46
引用
收藏
页码：S607 / S607
页数：1
相关论文
共 50 条
  • [1] Updated First-line Osimertinib in Asian patients with Advanced EGFR-mutated Lung Cancer
    Tan, W. L.
    Tan, S. H.
    Tan, D. S. W.
    Lai, G. G. Y.
    Ang, M. -K.
    Jain, A.
    Kanesvaran, R.
    Rajasekaran, T.
    Saw, S. P. L.
    Teh, Y. L.
    Chan, J.
    Ng, Q. S.
    Lim, D. W. -T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S652 - S653
  • [2] First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
    Ricciuti, Biagio
    Chiari, Rita
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S127 - S130
  • [3] Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers
    Qi, Chuang
    Cui, Huanxi
    Chen, Dongsheng
    [J]. JAMA ONCOLOGY, 2020, 6 (12)
  • [4] Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers Reply
    Schoenfeld, Adam J.
    Yu, Helena A.
    [J]. JAMA ONCOLOGY, 2020, 6 (12) : 1983 - 1983
  • [5] Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib
    Wu, Jia-Jun
    Tseng, Jeng-Sen
    Zheng, Zhe-Rong
    Chu, Cheng-Hsiang
    Chen, Kun-Chieh
    Lin, Mong-Wei
    Huang, Yen-Hsiang
    Hsu, Kuo-Hsuan
    Yang, Tsung-Ying
    Yu, Sung-Liang
    Chen, Jin-Shing
    Ho, Chao-Chi
    Chang, Gee-Chen
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [6] OSIMERTINIB MAY BE AN EFFECTIVE FIRST-LINE THERAPY IN EGFR-MUTANT NSCLC
    不详
    [J]. CANCER DISCOVERY, 2017, 7 (10) : 1061 - 1061
  • [7] Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue
    Piotrowska, Zofia
    Hata, Aaron N.
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (11) : 2441 - 2443
  • [8] CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC
    Hui, C.
    Wakelee, H. A.
    Neal, J. W.
    Ramchandran, K. J.
    Das, M.
    Nagpal, S.
    Roy, M.
    Huang, J.
    Pollom, E.
    Myall, N.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E110 - E110
  • [9] The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib
    Chen, Kuan-Chih
    Huang, Yen-Hsiang
    Hsu, Kuo-Hsuan
    Tseng, Jeng-Sen
    Chang, Gee-Chen
    Yang, Tsung-Ying
    [J]. ONCOTARGETS AND THERAPY, 2023, 16 : 317 - 326
  • [10] Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers
    Choudhury, Noura J.
    Marra, Antonio
    Sui, Jane S. Y.
    Flynn, Jessica
    Yang, Soo-Ryum
    Falcon, Christina J.
    Selenica, Pier
    Schoenfeld, Adam J.
    Rekhtman, Natasha
    Gomez, Daniel
    Berger, Michael F.
    Ladanyi, Marc
    Arcila, Maria
    Rudin, Charles M.
    Riely, Gregory J.
    Kris, Mark G.
    Heller, Glenn
    Reis-Filho, Jorge S.
    Yu, Helena A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : 463 - 475
12345